Our Impact
Our research results are changing the way patients are treated around the world.
- A new technique to prevent transmission of mitochondrial disease
- Approval of eculizumab and establishment of a national service to treat patients with Atypical Haemolytic Uraemic Syndrome
- Endocuff Vision: a simple tool to increase early detection of cancerous lesions in the colon
- The use of diet to reverse type 2 diabetes
- Ataluren: the first approved oral treatment for Duchenne muscular dystrophy
- Rucaparib for the treatment of germline and somatic HRD cancers
- Aspirin to decrease the risk of colorectal cancer for patients with Lynch syndrome
- Treatment stratification for medulloblastoma patients
- Human-derived limbal cell transplant to treat chemical burns of the eye
- Approval of the first licensed medication to treat drooling in children with neurodisability
- Optimising thrombectomy services to improve patient outcomes from stroke
- Erdafitinib, the first-in-class treatment of bladder cancer
- Skimune, a test for adverse immune reactions to compounds including chemical cosmetics and novel pharmaceuticals
